Randomized trial · people
Dulaglutide cut HbA1c and weight less than semaglutide in SUSTAIN 7
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this head-to-head trial, dulaglutide lowered blood sugar and weight, but less than semaglutide at both dose levels compared, with gut side effects common on both.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 1201
- Published
- 2018
- Journal
- Lancet Diabetes Endocrinol
What they tested
The team tested whether once-weekly semaglutide controls blood sugar at least as well as once-weekly dulaglutide and lowers body weight more, in people with type 2 diabetes.
How the study was done
A randomized, open-label trial (patients and doctors knew which drug was given) at 194 sites in 16 countries, in 1201 adults with type 2 diabetes not well controlled on metformin alone. Each person got one of four weekly shots for 40 weeks: dulaglutide at a low (0.75 mg) or high (1.5 mg) dose, or semaglutide at a low (0.5 mg) or high (1.0 mg) dose.

Model. Individual results vary.
What they found
HbA1c, a 3-month average of blood sugar, fell by 1.1 percentage points in the dulaglutide 0.75 mg arm and 1.4 points in the dulaglutide 1.5 mg arm, against 1.5 and 1.8 points with semaglutide 0.5 mg and 1.0 mg. Body weight fell by 2.3 kg with dulaglutide 0.75 mg and 3.0 kg with dulaglutide 1.5 mg, against 4.6 kg and 6.5 kg with the matching semaglutide doses; the estimated treatment differences favored semaglutide (-2.26 kg and -3.55 kg). Gut-related side effects were the most common problem: 33% of the dulaglutide 0.75 mg arm and 48% of the dulaglutide 1.5 mg arm, against 43% and 44% with semaglutide, and they were the top reason people stopped either drug. There were six deaths, two in each dulaglutide group and one in each semaglutide group.
What it doesn’t show
The trial was open-label and lasted 40 weeks, and everyone was also taking metformin, so it does not show results over longer periods or in other treatment settings. It was funded by Novo Nordisk.
The paper
Pratley et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018.
The compounds
More studies on Dulaglutide
- Mazdutide beat dulaglutide on HbA1c and weight at 28 weeksRandomized trial · people · 2026
- Dulaglutide: switching to tirzepatide beat dose escalation on HbA1cRandomized trial · people · 2025
- Dulaglutide cut HbA1c 1.3 vs 2.4 to 2.8 with tirzepatide at 52 weeksRandomized trial · people · 2022
- Dulaglutide lowered major cardiovascular events (HR 0.88) in REWINDRandomized trial · people · 2019
- 5-Amino-1MQ slowed bladder tumor growth in miceAnimal study · mice · 2024
- MOTS-c prevented muscle atrophy, raised muscle glucose uptake in miceAnimal study · mice · 2024
- Every study on Dulaglutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.